See more : True Corporation Public Company Limited (TRUE.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Annovis Bio, Inc. (ANVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Annovis Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Omni Ax’s Software Limited (OMNIAX.BO) Income Statement Analysis – Financial Results
- Gofore Oyj (GOFORE.HE) Income Statement Analysis – Financial Results
- Lendlease Global Commercial REIT (JYEU.SI) Income Statement Analysis – Financial Results
- Sincere Watch (Hong Kong) Limited (0444.HK) Income Statement Analysis – Financial Results
- Puig Brands SA (PUIG.MC) Income Statement Analysis – Financial Results
Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| General & Administrative | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Other Expenses | 0.00 | 0.00 | -36.75K | -1.16M | -735.08K | 0.00 | 0.00 |
| Operating Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Cost & Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Interest Income | 667.90M | 182.71K | 13.34K | 47.23K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 47.23M | 0.00 | 66.00 | 84.00 |
| Depreciation & Amortization | 1.00 | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| EBITDA | -45.04M | 0.00 | 0.00 | 0.00 | 0.00 | 66.00 | 84.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.04M | -25.51M | -14.54M | -6.64M | -1.61M | -713.94K | -682.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66.00 | 84.00 |
| Income Before Tax | -56.20M | -25.33M | -14.49M | -5.46M | -990.98K | -713.87K | -682.35K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -182.71K | -50.09K | -1.20M | -694.14K | -132.00 | -682.43K |
| Net Income | -56.20M | -25.15M | -14.44M | -4.26M | -296.84K | -713.87K | -682.35K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| EPS Diluted | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
| Weighted Avg Shares Out (Dil) | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson's Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
BERWYN, PA.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinson's Disease (PD) patients. The DSMB recommended that Annovis...
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
BERWYN, Pa. , June 8, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) and developing novel and transformative therapies, announced that its PD phase...
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent...
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a...
New Strong Buy Stocks for April 21st
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
New Strong Buy Stocks for April 18th
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
Annovis: Making Sense Of The Interim Analysis
Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months to improve communications leading up to the expected Phase...
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
BERWYN, Pa. , April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that in the last week it has raised aggregate gross proceeds of approximately...
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?
Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BERWYN, Pa. , April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed...
Source: https://incomestatements.info
Category: Stock Reports